Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
COMPASS Pathways Plc
CMPS
Healthcare
Biotechnology
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary...
psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CMPS)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(83)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 17, 2023 5:00am
COMPASS Pathways announces publication of positive data from
NEWS: $CMPS COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal
...more
(10)
•••
FukDaFed
X
View Profile
View Bullboard History
Post by
FukDaFed
on Feb 22, 2022 8:36pm
Buy for me here, stock seems cheap.
Stage 3 trials
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA
posted Apr 25, 2024 9:00am by
Indiva Ltd
-
|
“Net Income was just shy of break-even in Q4, which is a testament to the popularity of our products, our industry leading low-cost production platform, and our focus on cost control. Our core brands, namely Pearls by Grön, No Future, Bhang Chocolate and Indiva Blips continue to gain market share in Canada, as Indiva continues to hold the #1 market share position in edibles nationally," said ...read more
(30)
•••
MushLove
X
View Profile
View Bullboard History
Post by
MushLove
on Dec 12, 2021 4:00pm
The declining sp is affecting my mental health
This stock is not getting very much love.
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Nov 23, 2021 7:56am
Compass Pathways Granted Its Tenth Overall Patent Related To
Compass Pathways this morning issued a brief release, indicating it has been granted a fifth patent in the United States. The patent is related to what is referred to as crystalline psilocybin, and
...more
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Jun 28, 2021 7:38am
Compass Pathways Closes Enrollment For Phase IIb Psilocybin
Compass Pathways this morning provided a brief update to the market on the latest status of its ongoing phase IIb psilocybin therapy trial. The trials are being conducted to test the efficacy of
...more
(8)
•••
KandiBirdBoy
X
View Profile
View Bullboard History
Post by
KandiBirdBoy
on Apr 30, 2021 11:14am
RED LIGHT HOLLAND $TRIP 🍄🍄🍄🍄🍄$TRUFF
Entering Brazil , Oregon Rec Markets , Netherlands!!
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Mar 10, 2021 1:55pm
David Nutt: Amanita Muscaria Due For More Research – The Dai
Today host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the chair of the scientific advisory board for Compass Pathways, and a director of Psyched
...more
(27)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Mar 08, 2021 7:13pm
Great YT analysis on TRIP/TRUFF
https://youtu.be/k_2jeRmHL0I
(7)
•••
TraderLife
X
View Profile
View Bullboard History
Post by
TraderLife
on Feb 22, 2021 5:56pm
CMPS Stronger Move Than MMED
(3)
•••
Chris333
X
View Profile
View Bullboard History
Post by
Chris333
on Feb 03, 2021 11:07am
funny
I would need therapy after tripping with someone sober (watching me) and just laying on a table for 8 hours. Funny. That would be horrible.
(902)
•••
CommonCentsforDollars
X
View Profile
View Bullboard History
Post by
CommonCentsforDollars
on Jan 22, 2021 3:23pm
Horizons ETFs to Launch World's First Psychedelics-Focused E
Horizons ETFs to Launch World's First Psychedelics-Focused ETF https://markets.businessinsider.com/news/stocks/horizons-etfs-to-launch-world-s-first-psychedelics-focused-etf-1029994672 Maybe
...more
(14)
•••
SmallCapIntel
X
View Profile
View Bullboard History
Post by
SmallCapIntel
on Jan 18, 2021 8:09am
Updated & In-depth Psychedelics Stocks Index Jan 18!
Check out the biggest gainers and pullbacks from last week in this space: https://twitter.com/SagacityCm/status/1351150366071681025
(169)
•••
knowszero
X
View Profile
View Bullboard History
Comment by
knowszero
on Jan 11, 2021 1:32pm
RE:You are missing the big picture do some DD and act fast
The big picture is this guy says he's from outer space. Spamming everywhere about Myco. Only a fool would listen to anything this says.
(35)
•••
knowsbest
X
View Profile
View Bullboard History
Post by
knowsbest
on Jan 11, 2021 11:19am
You are missing the big picture do some DD and act fast
The real "GEM " is MYCO . mark this post .. act now and act decislively ..you can thank me later .
(6)
•••
Streetbrain
X
View Profile
View Bullboard History
Post by
Streetbrain
on Jan 11, 2021 8:56am
Neurotech Pioneer Kernel Partners with Cybin $CYBN
https://www.businesswire.com/news/home/20210111005430/en/Cybin-Partners-with-Kernel-to-Leverage-its-Breakthrough-Neuroimaging-Technology-for-Psychedelic-Therapeutics https://www.cybin.com/kernel/
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Stage Set for Creation of a Leading Intermediate Gold Producer
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil